Studies have indicated the therapeutic effects of engineered MSCs to express TRAIL in both cell lines or animal models of tumors, such as gliomas (118–120), colorectal carcinoma (121), and lung, breast, squamous, and cervical cancers (122). Here, TNFSF10 is linked to central nervous system cancer.